Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
B7-H1 Antigen
/ genetics
Cell Proliferation
Disease Progression
Female
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Immunogenetics
Male
Middle Aged
Neoplasms
/ drug therapy
Polymorphism, Single Nucleotide
Programmed Cell Death 1 Receptor
/ genetics
Vascular Endothelial Growth Factor Receptor-2
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 02 2020
27 02 2020
Historique:
received:
09
08
2019
accepted:
11
02
2020
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Hyperprogressive disease (HPD), an unexpected acceleration of tumor growth kinetics, is described in cancer patients treated with anti-PD-1/anti-PD-L1 agents. Here, our aim was to take into consideration the host and explore whether single nucleotide polymorphisms (SNPs) in key genes involved in immune response might predispose to HPD. DNA was extracted from blood-samples from 98 patients treated under CPI monotherapy. Four candidate genes (PD-1, PD-L1, IDO1 and VEGFR2) and 15 potential SNPs were selected. The TGK
Identifiants
pubmed: 32107407
doi: 10.1038/s41598-020-60437-0
pii: 10.1038/s41598-020-60437-0
pmc: PMC7046673
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
KDR protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3565Commentaires et corrections
Type : ErratumIn
Références
Bellmunt, J. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 376, 1015–1026, https://doi.org/10.1056/NEJMoa1613683 (2017).
doi: 10.1056/NEJMoa1613683
pubmed: 5635424
pmcid: 5635424
Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 375, 1856–1867, https://doi.org/10.1056/NEJMoa1602252 (2016).
doi: 10.1056/NEJMoa1602252
pubmed: 27718784
pmcid: 5564292
Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550, https://doi.org/10.1016/S0140-6736(15)01281-7 (2016).
doi: 10.1016/S0140-6736(15)01281-7
Horn, L. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924–3933, https://doi.org/10.1200/JCO.2017.74.3062 (2017).
doi: 10.1200/JCO.2017.74.3062
pubmed: 29023213
pmcid: 6075826
Motzer, R. J. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373, 1803–1813, https://doi.org/10.1056/NEJMoa1510665 (2015).
doi: 10.1056/NEJMoa1510665
pubmed: 26406148
pmcid: 5719487
Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372, 2521–2532, https://doi.org/10.1056/NEJMoa1503093 (2015).
doi: 10.1056/NEJMoa1503093
pubmed: 25891173
Borcoman, E. et al. Novel patterns of response under immunotherapy. Ann. Oncol. 30, 385–396, https://doi.org/10.1093/annonc/mdz003 (2019).
doi: 10.1093/annonc/mdz003
pubmed: 30657859
Saada-Bouzid, E. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 28, 1605–1611, https://doi.org/10.1093/annonc/mdx178 (2017).
doi: 10.1093/annonc/mdx178
pubmed: 28419181
Ferrara, R. et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA. Oncol. 4, 1543–1552, https://doi.org/10.1001/jamaoncol.2018.3676 (2018).
doi: 10.1001/jamaoncol.2018.3676
Mellema, W. W., Burgers, S. A. & Smit, E. F. Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report. Lung Cancer 87, 201–203, https://doi.org/10.1016/j.lungcan.2014.11.014 (2015).
doi: 10.1016/j.lungcan.2014.11.014
pubmed: 25488861
Champiat, S. et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin. Cancer Res. 23, 1920–1928, https://doi.org/10.1158/1078-0432.CCR-16-1741 (2017).
doi: 10.1158/1078-0432.CCR-16-1741
pubmed: 27827313
Kato, S. et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin. Cancer Res. 23, 4242–4250, https://doi.org/10.1158/1078-0432.CCR-16-3133 (2017).
doi: 10.1158/1078-0432.CCR-16-3133
pubmed: 28351930
pmcid: 5647162
Liu, X. S. & Mardis, E. R. Applications of Immunogenomics to Cancer. Cell 168, 600–612, https://doi.org/10.1016/j.cell.2017.01.014 (2017).
doi: 10.1016/j.cell.2017.01.014
pubmed: 28187283
pmcid: 5972371
Wartewig, T. et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nat. 552, 121–125, https://doi.org/10.1038/nature24649 (2017).
doi: 10.1038/nature24649
Fairfax, B. P. et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Sci. 343, 1246949, https://doi.org/10.1126/science.1246949 (2014).
doi: 10.1126/science.1246949
Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and Function of the PD-L1 Checkpoint. Immun. 48, 434–452, https://doi.org/10.1016/j.immuni.2018.03.014 (2018).
doi: 10.1016/j.immuni.2018.03.014
Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Sci. 359, 582–587, https://doi.org/10.1126/science.aao4572 (2018).
doi: 10.1126/science.aao4572
Nomizo, T. et al. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Sci. Rep. 7, 45124, https://doi.org/10.1038/srep45124 (2017).
doi: 10.1038/srep45124
pubmed: 28332580
pmcid: 5362817
Kim, Y. et al. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. J. Thorac. Oncol. 14, 1608–1618, https://doi.org/10.1016/j.jtho.2019.05.033 (2019).
doi: 10.1016/j.jtho.2019.05.033
pubmed: 31195179
Wang, Y. et al. Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Front. Pharmacol. 9, 536, https://doi.org/10.3389/fphar.2018.00536 (2018).
doi: 10.3389/fphar.2018.00536
pubmed: 29910728
pmcid: 5992436
Coelho, M. A. et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immun. 47, 1083–1099 e1086, https://doi.org/10.1016/j.immuni.2017.11.016 (2017).
doi: 10.1016/j.immuni.2017.11.016
Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461, https://doi.org/10.1016/j.ccell.2015.03.001 (2015).
doi: 10.1016/j.ccell.2015.03.001
pubmed: 25858804
pmcid: 4400238
Ben Nasr, M. et al. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med 9, https://doi.org/10.1126/scitranslmed.aam7543 (2017).
Sun, L. O. et al. Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed Cell Death through the TFEB-PUMA Axis. Cell 175, 1811–1826 e1821, https://doi.org/10.1016/j.cell.2018.10.044 (2018).
doi: 10.1016/j.cell.2018.10.044
pubmed: 30503207
pmcid: 6295215
Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930–934, https://doi.org/10.1093/nar/gkr917 (2012).
doi: 10.1093/nar/gkr917
pubmed: 22064851
Yoon, S. et al. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. J. Cancer Res. Clin. Oncol. 142, 1775–1780, https://doi.org/10.1007/s00432-016-2196-2 (2016).
doi: 10.1007/s00432-016-2196-2
pubmed: 27339628
Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes. Cancer 2, 1097–1105, https://doi.org/10.1177/1947601911423031 (2011).
doi: 10.1177/1947601911423031
pubmed: 22866201
pmcid: 3411125
Miettinen, M., Rikala, M. S., Rys, J., Lasota, J. & Wang, Z. F. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am. J. Surg. Pathol. 36, 629–639, https://doi.org/10.1097/PAS.0b013e318243555b (2012).
doi: 10.1097/PAS.0b013e318243555b
pubmed: 22314185
pmcid: 3310951
Zhu, P., Hu, C., Hui, K. & Jiang, X. The role and significance of VEGFR2(+) regulatory T cells in tumor immunity. Onco Targets Ther. 10, 4315–4319, https://doi.org/10.2147/OTT.S142085 (2017).
doi: 10.2147/OTT.S142085
pubmed: 28919780
pmcid: 5590762
Glubb, D. M. et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin. Cancer Res. 17, 5257–5267, https://doi.org/10.1158/1078-0432.CCR-11-0379 (2011).
doi: 10.1158/1078-0432.CCR-11-0379
pubmed: 21712447
pmcid: 3156871
Kim, J. Y. et al. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 11, https://doi.org/10.3390/cancers11111699 (2019).
Hwang, I., Park, I., Yoon, S. K. & Lee, J. L. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. Clin Genitourin Cancer, https://doi.org/10.1016/j.clgc.2019.09.009 (2019).
Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936–3943, https://doi.org/10.1158/1078-0432.CCR-13-0895 (2013).
doi: 10.1158/1078-0432.CCR-13-0895
pubmed: 23743568
pmcid: 3740724
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152, https://doi.org/10.1016/S1470-2045(17)30074-8 (2017).
doi: 10.1016/S1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420, https://doi.org/10.1158/1078-0432.CCR-09-1624 (2009).
doi: 10.1158/1078-0432.CCR-09-1624
pubmed: 19934295
López-Ratón, M., Rodríguez-Álvarez, M. X., Cadarso-Suárez, C. & Gude-Sampedro, F. OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. J. Stat. Softw. 61, 1–36 (2014).
doi: 10.18637/jss.v061.i08